CVS Health delivered a strong fourth quarter, with total revenues increasing by 8.2% to $105.7 billion, driven by growth across all operating segments. GAAP diluted EPS rose significantly to $2.30, while Adjusted EPS saw a slight decrease to $1.09 due to changes in Medicare Part D program seasonality. The company also achieved record full-year revenues of $402.1 billion.
Total revenues for Q4 2025 increased by 8.2% to $105.7 billion compared to the prior year.
GAAP diluted EPS for Q4 2025 was $2.30, a substantial increase from $1.30 in the prior year.
Adjusted EPS for Q4 2025 was $1.09, a decrease from $1.19 in the prior year, primarily due to Medicare Part D program seasonality changes.
Full-year 2025 total revenues reached a record high of $402.1 billion, up 7.8% from the prior year.
CVS Health confirmed its GAAP diluted EPS and Adjusted EPS guidance ranges for the full-year 2026, while updating its cash flow from operations guidance.
Analyze how earnings announcements historically affect stock price performance